PL2956163T3 - Kompozycje do leczenia patologicznego zwapnienia i kostnienia - Google Patents

Kompozycje do leczenia patologicznego zwapnienia i kostnienia

Info

Publication number
PL2956163T3
PL2956163T3 PL14751154.7T PL14751154T PL2956163T3 PL 2956163 T3 PL2956163 T3 PL 2956163T3 PL 14751154 T PL14751154 T PL 14751154T PL 2956163 T3 PL2956163 T3 PL 2956163T3
Authority
PL
Poland
Prior art keywords
ossification
compositions
treating pathological
pathological calcification
calcification
Prior art date
Application number
PL14751154.7T
Other languages
English (en)
Polish (pl)
Inventor
Demetrios Braddock
Ronald ALBRIGHT
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of PL2956163T3 publication Critical patent/PL2956163T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL14751154.7T 2013-02-13 2014-02-12 Kompozycje do leczenia patologicznego zwapnienia i kostnienia PL2956163T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764297P 2013-02-13 2013-02-13
US201361904786P 2013-11-15 2013-11-15
PCT/US2014/015945 WO2014126965A2 (en) 2013-02-13 2014-02-12 Compositions and methods for treating pathological calcification and ossification

Publications (1)

Publication Number Publication Date
PL2956163T3 true PL2956163T3 (pl) 2025-04-14

Family

ID=51354667

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14751154.7T PL2956163T3 (pl) 2013-02-13 2014-02-12 Kompozycje do leczenia patologicznego zwapnienia i kostnienia

Country Status (6)

Country Link
US (7) US9744219B2 (OSRAM)
EP (2) EP2956163B1 (OSRAM)
JP (4) JP6894664B2 (OSRAM)
ES (1) ES3014398T3 (OSRAM)
PL (1) PL2956163T3 (OSRAM)
WO (1) WO2014126965A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
USRE49529E1 (en) 2014-12-19 2023-05-16 Inozyme Pharma, Inc. Methods of treating tissue calcification
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
US20180371434A1 (en) * 2015-11-20 2018-12-27 Yale University Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
AU2017306549A1 (en) * 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
WO2019217373A1 (en) * 2018-05-08 2019-11-14 Yale University Compositions and methods for reducing progression of nephrolithiasis
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
CN116322742A (zh) * 2020-07-02 2023-06-23 依诺兹梅制药公司 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法
WO2022076848A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
US20020183276A1 (en) * 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2011113027A2 (en) * 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
KR101772366B1 (ko) 2011-03-11 2017-08-28 알렉시온 파마슈티칼스, 인코포레이티드 Ｎｐｐ１ 융합 단백질
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
USRE49529E1 (en) * 2014-12-19 2023-05-16 Inozyme Pharma, Inc. Methods of treating tissue calcification
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same

Also Published As

Publication number Publication date
JP2021143202A (ja) 2021-09-24
US9913881B2 (en) 2018-03-13
US20220152163A1 (en) 2022-05-19
US20150359858A1 (en) 2015-12-17
EP4523757A2 (en) 2025-03-19
JP2024026704A (ja) 2024-02-28
US20170354719A1 (en) 2017-12-14
US20200237882A1 (en) 2020-07-30
JP7420766B2 (ja) 2024-01-23
HK1214952A1 (en) 2016-08-12
EP4523757A3 (en) 2025-07-16
JP2019196392A (ja) 2019-11-14
US20170333533A1 (en) 2017-11-23
JP6894664B2 (ja) 2021-06-30
WO2014126965A3 (en) 2014-10-09
EP2956163A4 (en) 2017-03-22
EP2956163A2 (en) 2015-12-23
JP6944977B2 (ja) 2021-10-06
US20170252414A1 (en) 2017-09-07
US10624958B2 (en) 2020-04-21
US11266722B2 (en) 2022-03-08
WO2014126965A2 (en) 2014-08-21
EP2956163B1 (en) 2024-11-27
US10052367B2 (en) 2018-08-21
ES3014398T3 (en) 2025-04-22
JP2016509023A (ja) 2016-03-24
US20180318401A1 (en) 2018-11-08
US9744219B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
PL2956163T3 (pl) Kompozycje do leczenia patologicznego zwapnienia i kostnienia
SI2984166T1 (sl) Sestavki za zdravljenje MPSI
ZA201601970B (en) Compositions useful for treating disorders related to kit
IL246023B (en) Methods and preparations for the treatment of age-related conditions
IL245281A0 (en) Methods and preparations for the treatment of cancer
IL241078A0 (en) Synergistic preparations
GB201420103D0 (en) Treating particles
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
PL2792364T3 (pl) Kompozycja do zapobiegania lub do leczenia kaca
EP2989123A4 (en) METHODS AND COMPOSITIONS FOR TREATING COAGULATION DISORDERS
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
IL239680B (en) Preparations and methods for polynucleotide transfection
PT2968226T (pt) Composições de oxprenolol para tratamento do cancro
IL237483A0 (en) Preparations for the treatment of psoriasis
IL245703A0 (en) Methods and preparations for the treatment of amyloid deposits
ZA201507015B (en) Composition for treating hemorrhoids
EP2968550A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS
GB201302475D0 (en) Compositions and methods for treating biofilms
GB201302474D0 (en) Compositions and methods for treating biofilms
GB201302472D0 (en) Compositions and methods for treating biofilms
ZA201404930B (en) Plant treatment composition
GB201322764D0 (en) Treating places
GB201319951D0 (en) Treating Particle
AU2013903871A0 (en) Compositions for treating skin conditions